-
When President George W. Bush announced at his January State of the Union address that he would provide a five-year, $15 billion Emergency Plan for AIDS Relief worldwide, his efforts were lauded internationally.
-
-
The FDAs accelerated approval of Fuzeon (enfuvirtide) for use in combination with other anti-HIV medications has drawn mixed reactions: excitement that a new class of drugs is now on the market and disappointment that its manufacturer, Trimeris, has priced the drug so high.
-
The National Association of State and Territorial AIDS Directors (NASTAD) in Washington, DC, has a Viral Hepatitis Program that provides guidance and information for HIV/AIDS programs. The materials help staff develop training on viral hepatitis and assess how to incorporate viral hepatitis issues into their existing program.
-
Ask public health officials what behaviors are driving the recent syphilis epidemics, and their answers are limited at best. That may change in the next year as the Centers for Disease Control and Prevention (CDC) implements behavioral surveillance systems in 15 cities across the country.
-
As HIV continues to spread faster in the South than in any other region, health officials from 13 states are sending out a strong message: The South needs help fighting an epidemic that is becoming increasingly rural, female, African-American, and poor.
-
-
Its back to the research drawing board in the search for more treatment options for genital herpes. A clinical trial of an experimental drug, resiquimod, has been suspended since preliminary data showed it was not as effective as expected.
-
The news is in from the worlds first large-scale trial of a HIV vaccine, and it isnt good: The vaccine failed to achieve a statistically significant reduction of HIV infection within its study population as a whole.
-
Epidemiological evidence presented at a recent Bethesda, MD-based National Cancer Institute (NCI) workshop could help end a longstanding debate on the question of induced abortion and risk of breast cancer.